In a significant breakthrough for pediatric and adolescent brain cancer treatment, SunAct Cancer Institute has announced that it will become the first in the country to offer CAR-T therapy for Midline Glioma, a devastating disease with historically poor outcomes. The emergence of CAR-T therapy for Midline Glioma has seen a major game-changing shift in treatment strategies, providing renewed hope for families confronting this devastating diagnosis.“Earlier this month we commemorated the International Childhood Cancer Day on February 15 and we believe our offering today marks the beginning of a new era in neuro-oncology, where we can harness the power of a patient’s immune system to fight an otherwise untreatable disease,” said Dr. Vijay Patil, Founder of SunAct Cancer Institute. “CAR-T therapy in Midline Gliomas represents an exciting step forward, and with continued research and clinical trials, we hope to transform survival outcomes for these young patients.”Midline Glioma is among the most aggressive forms of brain cancer, primarily affecting young patients. Despite current standard treatments—including biopsy, radiation, temozolomide chemotherapy, and ONC-201 therapy—survival rates remain dismal, with a median survival of less than a year.However, new advancements in cellular therapies, particularly CAR-T therapy, are offering a beacon of hope. GD-2 CAR-T therapy, first highlighted in Nature in November 2016, has demonstrated promising results, marking a pivotal shift toward precision medicine in treating these aggressive tumors.As research and clinical trials progress, these groundbreaking therapies may soon redefine survival expectations and establish a new standard of care for patients battling this aggressive cancer.